Fredag 6 Juni | 12:20:19 Europe / Stockholm
Svenska | English

AlzeCure Pharma

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Est. tid*
2025-11-11 08:00 Kvartalsrapport 2025-Q3
2025-08-26 08:00 Kvartalsrapport 2025-Q2
2025-05-15 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2025-05-14 - Årsstämma
2025-05-05 - Kvartalsrapport 2025-Q1
2025-02-27 - Bokslutskommuniké 2024
2024-11-11 - Kvartalsrapport 2024-Q3
2024-08-26 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2024-05-14 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-04-25 - Extra Bolagsstämma 2023
2024-02-27 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2023-05-17 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-29 - Extra Bolagsstämma 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-18 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2021-05-17 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-11-17 - Kvartalsrapport 2020-Q3
2020-08-25 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2020-05-20 - Årsstämma
2020-04-29 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-08-31 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2019-05-22 - Årsstämma
2019-05-01 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AlzeCure Pharma är ett läkemedelsbolag. Bolaget har sin inriktning mot forskning och utveckling av läkemedel som används för diverse hjärnsjukdomar, med störst fokus mot Alzheimers sjukdom, men även mot smärta. Teknologin och forskningen utgår ifrån egen läkemedelsplattform, där bolaget utvecklar olika symptomlindrande och sjukdomsmodifierande läkemedelskandidater. Huvudkontoret ligger i Huddinge.
AlzeCure Pharma to present at Stora Aktiedagarna in Stockholm on June 10
2025-06-03 10:00:00

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company’s CEO Martin Jönsson will present at Stora Aktiedagarna in Stockholm, Sweden, hosted by Aktiespararna, at 08:50 CET on June 10.

In his presentation, Martin Jönsson will highlight the company's project portfolio and drug candidates from the research platforms NeuroRestore®, Alzstatin® and Painless. The presentation will be followed by a Q&A led by Aktiespararna’s moderator.

The live broadcast is available via the following link:https://invitepeople.com/public/events/bb6e31a6f2/pages/bb79be3286

The presentation will also be available on the company's website afterwards: https://www.alzecurepharma.se/en/presentations-and-interviews/

For more information about the event and to register to attend the Birger Jarl Conference in Stockholm, please see here: https://invitepeople.com/events/bb6e31a6f2

Event time: June 10, 08:00 CET – June 11, 19:00 CET
Presentation time: June 10, 08:50 CET
Venue: Birger Jarl Konferens, Birger Jarlsgatan 61 A, Stockholm, Sweden

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se.

Image Attachments

Martin Jönsson CEO AlzeCure Pharma

Attachments

AlzeCure Pharma to present at Stora Aktiedagarna in Stockholm on June 10

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden